FDA clears absorbable soft-tissue marker from Augmenix

01/29/2013 | AuntMinnie.com (free registration)

The FDA has given Augmenix 510(k) clearance to market TraceIT, an injectable synthetic hydrogel used to mark soft tissue radiographically before surgery. The technology, which can be viewed through MRI and other ultrasound modalities, is designed to help streamline image fusion and enhance soft-tissue alignment.

View Full Article in:

AuntMinnie.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL